Clinical Trial Update: Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial update on neoadjuvant pembrolizumab for unresectable stage III/IV melanoma; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Unresectable Malignant Neoplasm

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: St. Louis University | Conditions: Unresectable Malignant Neoplasm, Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2019-06-20